These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8145429)

  • 21. Trial clouds use of niacin with a statin.
    Harv Heart Lett; 2011 Aug; 21(12):2. PubMed ID: 21991606
    [No Abstract]   [Full Text] [Related]  

  • 22. Nicotinic acid as a lipid-modifying drug--a review.
    Julius U; Fischer S
    Atheroscler Suppl; 2013 Jan; 14(1):7-13. PubMed ID: 23357134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niacin aids cholesterol control. But choose "extended release" to minimize "flushing" risk.
    Heart Advis; 2003 Jul; 6(7):3. PubMed ID: 12921040
    [No Abstract]   [Full Text] [Related]  

  • 24. New thinking on niacin use. Using niacin to raise "good" cholesterol doesn't lower your risk of having a heart attack or stroke.
    Harv Health Lett; 2014 Aug; 39(10):6. PubMed ID: 25230410
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients.
    Bays HE; Maccubbin D; Meehan AG; Kuznetsova O; Mitchel YB; Paolini JF
    Clin Ther; 2009 Jan; 31(1):115-22. PubMed ID: 19243712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safety and tolerability of nicotinic acid. Results of the multicenter, open, prospective NAUTILUS study].
    Vogt A; Kassner U; Hostalek U; Peiter A; Steinhagen-Thiessen E
    MMW Fortschr Med; 2006 May; 148(18):41. PubMed ID: 16736688
    [No Abstract]   [Full Text] [Related]  

  • 28. Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
    Harv Health Lett; 2007 Apr; 32(6):6. PubMed ID: 17390509
    [No Abstract]   [Full Text] [Related]  

  • 29. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
    Brinton EA; Kashyap ML; Vo AN; Thakkar RB; Jiang P; Padley RJ
    Am J Cardiovasc Drugs; 2011 Jun; 11(3):179-87. PubMed ID: 21619381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Niacin: vitamin and antidyslipidemic drug.
    Jacobson EL; Kim H; Kim M; Jacobson MK
    Subcell Biochem; 2012; 56():37-47. PubMed ID: 22116693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 33. A new niacin. Vitamin with an HDL kick.
    US News World Rep; 2001 Apr; 130(15):54. PubMed ID: 11330168
    [No Abstract]   [Full Text] [Related]  

  • 34. Nicotinic acid: pharmacological effects and mechanisms of action.
    Gille A; Bodor ET; Ahmed K; Offermanns S
    Annu Rev Pharmacol Toxicol; 2008; 48():79-106. PubMed ID: 17705685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug treatment of hypercholesterolaemia in a patient with Gilbert's syndrome.
    Cummings MH; Watts GF
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():383-5. PubMed ID: 7979108
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of high blood cholesterol in patients with coronary heart disease].
    Nagai Y; Yamashita S
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():675-81. PubMed ID: 12735049
    [No Abstract]   [Full Text] [Related]  

  • 37. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.
    McKenney JM; Proctor JD; Harris S; Chinchili VM
    JAMA; 1994 Mar; 271(9):672-7. PubMed ID: 8309029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effect of enduracin on the activity of a cholesterol ester transfer protein in blood plasma of people with hypercholesteremia].
    Gorshkova IN; Kiseleva NG; Akhmedzhanov NM; Perova NV
    Biull Eksp Biol Med; 1996 Feb; 121(2):185-7. PubMed ID: 9026127
    [No Abstract]   [Full Text] [Related]  

  • 39. Extended-release niacin raises adiponectin and leptin.
    Westphal S; Borucki K; Taneva E; Makarova R; Luley C
    Atherosclerosis; 2007 Aug; 193(2):361-5. PubMed ID: 16887123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist.
    Tang H; Lu JY; Zheng X; Yang Y; Reagan JD
    Biochem Biophys Res Commun; 2008 Oct; 375(4):562-5. PubMed ID: 18722346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.